Plasma concentrations of selected organobromine compounds and polychlorinated biphenyls in postmenopausal women of Quebec, Canada.

Background: Brominated flame retardants, especially polybrominated diphenyl ethers (PBDEs), have been widely used in North America, but little is known about the level of exposure of human populations to these compounds.

Objectives: We set out to assess the internal exposure of postmenopausal Canadian women to selected organobromine compounds and to investigate factors associated with this exposure.

Methods: We measured concentrations of four PBDEs, one polybrominated biphenyl, and for comparative purposes, 41 polychlorinated biphenyl (PCB) congeners in plasma samples from 110 healthy postmenopausal women who were recruited at a mammography clinic in 2003-2004.

Results: PBDE-47 was the major PBDE congener, with a mean (geometric) concentration of 8.1 ng/g lipids and extreme values reaching 1,780 ng/g. By comparison, the mean concentration of the major PCB congener (PCB-153) was 41.7 ng/g and the highest value was 177 ng/g. PBDEs 47, 99, and 100 were strongly intercorrelated, but weaker correlations were noted with PBDE-153. As the sum of PBDEs ([SIGMA]PBDEs) increased, the relative contribution of PBDE-47 to the [SIGMA]PBDEs increased, whereas that of PBDE-153 decreased. PBDE-153 was the only brominated compound correlated to PCB-153. PBDE levels were not linked to any sociodemographic, anthropometric, reproductive, or lifestyle variables documented in the present study. Age and body mass index gain since the age of 18 years were significant predictors of PCB-153 plasma levels.

Conclusion: Our results suggest that exposure to PBDE-47 likely occurs through direct contact with the penta-PBDE formulation, whereas exposure to PBDE-153 may originate in part from the food chain.

Key Words: brominated flame retardants, polybrominated biphenyls, polybrominated diphenyl ethers, polychlorinated biphenyls, postmenopausal women, Quebec, Canada. Environ Health Perspect 115:1429-1434 (2007). doi:10.1289/ehp.10303 available via http://dx.doi.org/ [Online 24 July 2007]

Organobromine compounds such as polybrominated diphenyl ethers (PBDEs) are now largely distributed in the environment because of their wide use as flame retardants in electronic equipment, plastics, and textiles. Several PBDE congeners, their hydroxylated metabolites, and brominated bisphenol A analogs induce the estrogen-receptor signal transduction pathway in vitro and may therefore increase the risk of hormone-related diseases (Meerts et al. 2001). Studies in Sweden have revealed that PBDEs increased in human breast milk over the last decades (Meironyte et al. 1999; Noren and Meironyte 2000). However, in recent years a decrease in concentrations has been noted in Sweden (Lind et al. 2003). A similar decline in levels has not been reported in plasma samples from people in North America; to the contrary, limited data for the U.S. population indicate a steep increase in PBDE blood concentrations between 1973 and 2003 (Schecter et al. 2005b). The human levels in North America are also, in general, considerably higher than in any other parts of the world.

In the course of a pilot study investigating possible environmental risk factors of breast cancer, we analyzed plasma samples obtained from 110 healthy postmenopausal women living in the Quebec City area (Quebec, Canada) for several persistent organic pollutants. In this article we present the concentrations of 4 PBDE, 1 polybrominated biphenyl (PBB), and 41 polychlorinated biphenyl (PCB) congeners, the latter for comparative purposes. We also investigated the relation between concentrations of these compounds and anthropometric, demographic, reproductive, and lifestyle characteristics of participants.

Material and Methods

Population. We recruited a convenience sample of 110 women at a large mammography screening clinic located in Quebec City. All women attending the clinic between July 2003 and March 2004 were given a pamphlet describing the purpose of the study and a form to complete (name and coordinates) if they were interested in participating. A research nurse later contacted by telephone each woman who showed interest to verify her eligibility and schedule an appointment for a face-to-face interview. Women were eligible if a) they were postmenopausal; b) they had no history of breast cancer; c) they had no history of health problems related to steroid hormone metabolism, hepatic, thyroid, or adrenal disease; and d) they had not taken hormone replacement therapy during the last 3 months. Women agreeing to participate provided informed consent including authorization for blood sampling and banking.The protocol of the study was approved by the Research Ethics Review Board of Hopital St-Sacrement - Centre Hospitalier Affilie Universitaire de Quebec.

During the face-to-face interview, the research nurse documented participant gynecologic and reproductive histories, current diseases and drug intake, lifestyle habits, and the consumption of some food items including meat. Women were queried about their weight and height at 18 years of age. The research nurse also recorded current anthropometric measures (weight, height, waist circumference) and collected blood samples (75 mL) for various biomarker measurements. Blood specimens were collected in vacutainers with EDTA as the anticoagulant and were kept on ice until transported by medical courier to the laboratory at the end of each morning and afternoon. Blood was processed within 2-3 hr of collection. Samples were centrifuged and the plasma aliquoted and stored at -80[degrees]C in glass vials (prewashed with hexane) until analysis.

Analytical procedure. Plasma samples were extracted on an Oasis HLB (540 mg; Waters Corp., Milford, MA, USA) solid phase extraction (SPE) column according to the method presented by Sandau et al. (2003). Internal standards were added to 5 mL of plasma prior to formic acid (5 mL) and deionized water (5 mL). The mixture was vortexed for 1 min and left overnight in the refrigerator. The HLB column was conditioned with dichloromethane (5 mL), followed by 5% methanol in 0.1 M hydrochloric acid (5 mL). The sample was then slowly applied to the column at a flow rate of 0.38 mL/min. After drying the column with pressurized nitrogen, the sample was extracted using 10% methanol in dichloromethane (15 mL). The sample was evaporated to dryness to ensure that all methanol was removed from the sample before it was redissolved in 0.5 mL n-hexane. The extract was subsequently eluted through a column containing 1 g activated Florisil (60-100 mesh; Fisher Scientific, Pittsburgh, PA, USA). The fraction containing the PBDEs was eluted using hexane/dichloromethane (9/1; 9 mL). The extraction and cleanup procedures were automated using a Rapidtrace Automated SPE workstation (Zymark Corp., Hopkinton, MA, USA), and evaporation was performed using a heated vacuum evaporator (Rapidvap; Labconco Corp., Kansas City, MO, USA). [.sup.13][C.sub.12]-PBDE-77 was used as the internal standard for the PBDEs, and four different [.sup.13][C.sub.12]-PCBs (PCBs 77, 101, 141, and 178) were used as internal standards for the PCBs (Cambridge Isotope Laboratories, Andover, MA, USA).

Samples were analyzed on an Agilent 6890N gas chromatograph equipped with split/splitless injector, Agilent 7683 autosampler, Agilent DB-XLB column (60 m; 0.25 mm i.d., 0.25 [micro]m film thickness), coupled with an Agilent 5973N mass spectrometer (Agilent Technologies, Wilmington, DE, USA). The carrier gas (helium) flow was 0.8 mL/min (flow controlled). The temperature program was as follows: 100[degrees]C (1 min), 10[degrees]C/min to 200[degrees]C (0 min), 1.5[degrees]C/min to 240[degrees]C (10 min), 20[degrees]C/min to 330[degrees]C (10 min). The injector and transfer lines were kept at 270[degrees]C and 280[degrees]C, respectively. The injection volume was 2 [micro]L, injected in a pulsed splitless mode.

The mass spectrometer was operated in selected ion monitoring mode, using electron capture negative ionization with methane (99.97% purity) as the reagent gas. The ion source and quadropole temperatures were set to 150[degrees]C and 103[degrees]C, respectively. Masses 79 and 81 were monitored for all brominated compounds. For PCBs, the molecular ion and M-2 fragment ion were monitored as the target and confirmation ions. The target ion was employed for quantification, and the confirmation ion from the same isotopic cluster was used to confirm the identity of the compound.

We determined concentrations of total cholesterol, free cholesterol, triglycerides, and phospholipids in plasma samples by enzymatic methods. The total plasma lipid concentration was calculated according to the equation proposed by Akins et al. (1989).

Quality assurance/quality control. The accuracy of the analytical method was assured through analysis of certified reference materials and participation in international interlaboratory comparison programs both for PCBs and PBDEs. In addition, the precision was monitored by analyzing 15 samples from a control serum pool. The analysis of the serum pool samples gave reproducible results for the BDEs. For PBDE-47, the mean concentration of the control pool samples was 422 ng/L and the coefficient of variation (CV) was 11%. For comparison, the mean PCB-153 concentration was 328 ng/L and the CV was 6%. The accuracy of the PBDE and PCB analyses was assured through the quantification of the NIST SRM (standard reference material) 1589a (National Institute of Standards and Technology, Gaithersburg, MD, USA). The mean concentration of PBDE-47 measured in this reference material was 193 ng/L, a value 12% above the mean reference value of 172 ng/L (range, 162-182 ng/L). For PBDE-99, we obtained a mean value of 48 ng/L, which is 20% above the reference value of 39.9 ng/L (range, 34.7-45.1 ng/L). For PBDE-100 we obtained the same value as the reference value (i.e., 25 ng/L). For PCB-153, the mean concentration was 833 ng/L, which is 11% below the reference value of 936 ng/L (range, 891-981 ng/L). The average concentration of PBDE-47 in blank samples was 16 ng/L (SD, 5 ng/L). For PBDEs 99 and 100, the blank values were 10 and 2 ng/L, respectively. PBDE-153, PBB-153, and PCB-153 were not detected in blanks. The blank values were subtracted from all concentrations before the results were reported. The recovery rates for [.sup.13][C.sub.12]-PBDE-77 were between 40 and 90%. The recovery rates for [.sup.13][C.sub.12]-PCBs were between 50 and 95%. The limit of detection (LOD) was 4 ng/L for PBDE-47 and 2 ng/L for the other PBDE congeners and PBB-153. The LOD ranged from 3 to 5 ng/L for PCB congeners.

Statistics. We used the SPSS software package (v. 11.0; SPSS, Chicago, IL, USA) to perform all statistical analyses. PBDEs and PCBs plasma concentrations were log-transformed before correlation and multiple linear regression analyses because the distributions of values were skewed to the right. We performed multiple linear regression analyses to determine predictors of PBDE and PCB plasma levels. Independent variables of interest for these analyses were age, body mass index (BMI), BMI gain since 18 years of age, parity and breast-feeding history, meat consumption, alcohol consumption, and smoking habits. Results from multiple linear regressions were analyzed for the detection of multicolinearity problems. Statistical tests were two-sided, and a confidence level of 0.05 was used as the criteria for statistical significance.

Results

The characteristics of participating women are shown in Table 1. The mean age of the 110 women was 58.3 years (range, 48-76 years). All were Caucasian except for one woman of Mediterranean origin. Twenty-five percent of the women were nulliparous, and 13% had had [greater than or equal to] 4 children. Of the 83 parous women, 40 (48.2%) never breast-fed. Only 7.3% of participants were current smokers, and they smoked an average of 12 cigarettes/day (range, 3-30). The vast majority (93.6%) of women had consumed alcohol during the year before the interview, and 30% had done so the day before the interview. Mean alcohol intake was one-half of a drink per day, ranging from 0 to 3 drinks/day. More than twothirds of women had reached the college or university level of education. In general, women with more education tended to consume more alcohol, to breast-feed more, and had a lower BMI.

Table 1. Selected characteristics of the 110 postmenopausal women,
Quebec, Canada.


Characteristic              No. (%)    Mean [+ or -]SD    Range

Age (years)                            58.3 [+ or -]5.6   48 to 76

Weight (kg)                            68.7 [+ or -]14.0  44.8 to 133.0

Height (cm)                            160 [+ or -]5.2    146 to 172

BMI (kg/m2)                            27.0 [+ or -]5.4   17.2 to 51.3

BMI gain since 18 years of             6.4 [+ or -]5.4    -14.7 to 28.0
age (kg/[m.sup.2])

No. of children                        1.9 [+ or -]1.4    0 to 5

Cumulative breast-feeding              12.9 [+ or -]26.5  0 to 124.3
duration (weeks)

Alcohol consumption (no.               0.46 [+ or -]0.56  0 to 3
of drinks/day)

Meat consumption (g/day)               59.7 [+ or -]46.2  1.8 to 220.0

Smoking

Current                      8 (7.3)

Ever                        54 (49.1)

Never                       48 (43.6)

Level of education

Primary                      9 (8.2)

High school                 26 (23.9)

College or university       75 (68.2)

The concentrations of the four PBDE congeners and PBB-153 are shown in Table 2. PBDE-47 was the congener with the highest geometric mean (GM) concentration (8.1 ng/g lipids) and was detected in all samples. It was the major congener in 96.4% of the participants (106/110). PBDEs 99, 100, and 153 were also frequently detected ([greater than or equal to] 83% of samples), but they were present in much lower concentrations (GM concentrations ranging from 1.1 to 1.4 ng/g lipids). PBDE-153 was the dominant congener in 3.6% of the participating women (4/110). PBB-153 was detected in only 30% of the samples, at levels considerably lower than those of the PBDEs. The arithmetic means of untransformed values were considerably higher than the median values for the PBDEs due to three women with very high levels. The maximum value observed for PBDE-47 was 1,780 ng/g lipids (Table 2). This concentration is 10 times higher than the highest value observed for PCB-153 (177 ng/g lipids), which is the most abundant PCB congener (Table 3). Several other brominated compounds were also detected in the samples with elevated values. These were not identified due to lack of standards.

Table 2. Lipid weight concentrations (ng/g lipids) of selected
organobromine compounds in plasma samples from 110 postmenopausal women,
Quebec, Canada.

Compounds      Mean     GM     Range     Percent
                                         detected

PBDEs

 PBDE-47       39.0    8.10  0.81-1,780    100

 PBDE-99       11.6    1.40  <0.40-716      90

 PBDE-100       6.79   1.10  <0.40-366      83

 PBDE-153       5.38   1.35  <0.40-198      96

 [SIGMA]PBDEs  63.7   13.4    0.81-3,060   100

PBB-153         0.46   0.22  <0.40-20.1     30

A value equal to one-half the LOD was substituted for nondetects to
calculate mean values.
Table 3. Lipid weight concentrations (ng/g lipids) of PCB congeners in
plasma samples from 109 postmenopausal women, Quebec, Canada.

  Congener     Mean   GM     Range     Percent
                                       detected

PCB-74       10.8   9.41  <3.80-50.5        97
PCB-99       9.14   6.66  <1.41-64.3        94
PCB-105      2.30   1.80  <1.00-13.4        69
PCB-118      13.1  11.2    3.81-69.9       100
PCB-138      25.9  22.7    5.45-101        100
PCB-146      4.72   4.01   1.55-33.8       100
PCB-153      47.1  41.7   14.4-177         100
PCB-156      5.36   4.77   2.15-24.7       100
PCB-163      17.1  14.5    5.39-124        100
PCB-167      1.60   1.30   <0.96-8.52       66
PCB-170      12.9  11.4    5.57-65.2       100
PCB-172      1.62   1.30  <0.72-11.5        64
PCB-177      1.76   1.46  <0.80-8.68        72
PCB-178      2.29   1.80  <0.94-19.6        81
PCB-180      40.4  34.7    1.39-206        100
PCB-183      3.09   2.71  <1.30-9.3         96
PCB-187      9.00   7.56   2.26-62.2       100
PCB-194      7.35   6.36  <0.57-42.1        99
PCB-195      1.20   1.01  <0.72-5.44        50
PCB-196      2.10   1.78  <0.80-9.09        84
PCB-199      2.64   2.20  <1.06-17.8        88
PCB-203      4.53   4.04  <0.82-21.1        99
PCB-206      2.47   2.11  <0.94-13.3        90
PCB-209      1.19   0.92  <0.60-8.19        60
[SIGMA]PCBs  229  204     93.1-1,010

Only congeners detected in > 50% of the samples are listed. A value
equal to one-half of the LOD was substituted for nondetects to
calculate mean values. n= 109 (analytical problems were encountered
with one sample).

As mentioned above, distributions of PBDE and PCB congener concentrations were skewed right and values were log-transformed prior to performing statistical analyses. Three women were still considered outliers on the basis of their log-transformed [SIGMA]PBDE (sum of PBDEs) concentrations that exceeded the mean value plus 4 SDs. These women were removed before performing additional statistical analyses that aimed at identifying factors associated with PBDE concentrations.

PBDEs 47, 99, and 100 were highly intercorrelated (Pearson's r > 0.86; p < 0.001; Figure 1A, B). PBDE-153 behaved differently from the other PBDEs, as it was not as highly correlated to the other congeners; for example, the correlation coefficient between PBDE-153 and PBDE-47 was 0.53 (p < 0.001; Figure 1C). PBDEs 47, 99, and 100 were not correlated to PCB-153. Only PBDE-153 was weakly correlated to PCB-153 (r = 0.19; p = 0.046; Figure 1D). The relative contribution of PBDE-47 to the [SIGMA]PBDEs increased with the increasing [SIGMA]PBDEs (Figure 2A), as opposed to PBDE-153, which represented a decreasing proportion of the [SIGMA]PBDEs as the [SIGMA]PBDEs increased (Figure 2B).

The lipid-adjusted concentrations of PCB congeners that were detected in [greater than or equal to] 50% of the samples are presented in Table 3. Congeners that were detected in < 50% of the samples were PCBs 28, 44, 49, 52, 70, 82, 87, 101, 110, 128, 151, 158, 169, 171, 191, 205, and 208. These congeners are not discussed further and are not included in [SIGMA]PCB values. The dominating PCB congener was PCB-153, with a GM concentration of 41.7 ng/g lipids (range, 14.4-177), followed by PCBs 180, 138, 163, and 118. The GM [SIGMA]PCB level was 204 ng/g lipids (range, 93.1-1,010). Concentrations of the major PCB congeners and of total PCBs were highly intercorrelated (data not shown), and the major congener, PCB-153, was used in the statistical analyses as a surrogate of PCB exposure.

We tested age, BMI, BMI gain since the age of 18 years, parity, cumulative breastfeeding duration, meat consumption, alcohol consumption, and smoking habits for associations with levels of PBDEs and PCBs (PCB-153 as the surrogate). None of these factors was related to the plasma concentrations of PBDEs. Current BMI and BMI gain since 18 years of age were negatively correlated to PCB-153 plasma concentrations (current BMI: r = -0.40, p < 0.001; BMI gain: r = -0.54, p < 0.001), whereas age was positively related to PCB-153 concentrations (r = 0.23, p = 0.015). Multiple linear regression analyses revealed that PCB-153 levels were positively associated with age (p = 0.01) and negatively associated with BMI gain (p < 0.001). Current BMI was also positively related to PCB-153 concentrations in the final model, although the association did not reach statistical significance (p = 0.06). The total model explained 34% of the variance in PCB-153 concentrations (Table 4).

Table 4. Multiple linear regression analysis of log-transformed
PCB-153 concentrations (ng/g lipids) in plasma samples from 109
postmenopausal women, Quebec, Canada.

                   Unstandardized         Standardized
                         B           SE        [beta]     p-Value

Age at                    0.007  0.003         0.202    0.012
interview
(years)

Current BMI               0.013  0.007         0.336    0.058
(kg/[m.sup.2])

BMI gain since           -0.031  0.007        -0.827  < 0.001
18 years of age
(kg/[m.sup.2])

Model adjusted [R.sup.2] = 0.335; n= 109 (analytical problems were
encountered with one sample).

We analyzed plasma samples collected from postmenopausal women residing in the Quebec City area for PBDEs, which along with other brominated flame retardants are emerging as contaminants of interest because of their persistence and toxicologic properties similar to those of PCBs. Although mean concentrations of PBDE congeners were much lower than those of major PCB congeners, a few women displayed high PBDE concentrations that exceeded those of major PCBs by an order of magnitude, suggesting that sources of direct exposure are still present in the home and the workplace (Birnbaum and Hubal 2006).

Comparative data from studies conducted in the United States and Europe are presented in Table 5. For these comparisons we have not distinguished between different age groups or sex because there have been no previous reports of levels of PBDEs increasing with age or being different in men and women (Birnbaum and Hubal 2006). Because PBDEs are lipophilic compounds, we present data on a lipid basis to ensure their comparability, whatever the biological sample analyzed (whole blood, serum, plasma, or adipose tissue). From the data presented in Table 5, it is clear that the levels of PBDEs in the women from Quebec are substantially (up to 10-fold) higher than the levels in Europe. The levels of PBDEs in our sample of women from Quebec clearly support previous findings of concentrations being considerably higher in North America compared with other parts of the world. The Quebec levels do seem a little lower than those in the United States (Table 5).

Table 5. Comparison of PBDE and PCB-153 levels in the present study
with concentrations from other studies conducted elsewhere in the world.

Reference                    PBDE-47  PBDE-99  PBDE-100  PBDE-153

Present study                 8.1      1.4      1.1       1.4
Schecter etal. 2005b         12.8      3.2      2.6       3.6
Sjodin etal. 2004            34       11        5.9       7.3
Johnson-Restrepo etal. 2005  29.3     10.3     12.0      <1
Weiss etal. 2006              0.91     0.20     0.29      1.1
Thomas etal. 2006             0.82    <0.16     0.76      1.7
Fangstrom etal. 2005          1.3      0.33     0.51      1.0
Naert etal. 2006              0.88     0.47     0.72      2.40

Reference                    PCB-153       Medium       Age     Sex

Present study                41.7 (a)      Plasma      48-76  Female
Schecter etal. 2005b                       Blood       22-91   Both
Sjodin etal. 2004            35            Serum         ?     Both
Johnson-Restrepo etal. 2005  35.2 (b)  Adipose tissue  18-51   Both
Weiss etal. 2006             260           Serum       52-81  Female
Thomas etal. 2006            41            Serum       22-80   Both
Fangstrom etal. 2005         430           Serum         ?    Female
Naert etal. 2006             274       Adipose tissue  19-84   Both

Reference                        Country       No.

Present study                    Canada      110
Schecter etal. 2005b         United States    39
Sjodin etal. 2004            United States   Pool
Johnson-Restrepo etal. 2005  United States    52
Weiss etal. 2006                 Sweden       53
Thomas etal. 2006            United Kingdom  154
Fangstrom etal. 2005             Faroes       57
Naert etal. 2006                 Belgium        53

All levels are either GMs or medians and are expressed on a lipid
basis (ng/g lipids).

(a) n= 109. (b) Sum of hexa-chlorinated congeners.

In our group of Quebec women, PBDE-47 is the dominating congener, and that also seems to be the case in the samples from the United States (Table 5). In European samples, however, PBDE-153 is often the dominating congener (Fangstrom et al. 2005; Johnson-Restrepo et al. 2005; Morland et al. 2005; Schecter et al. 2003). This difference in congener patterns between Europe and North America may be explained by differences in the use of penta-PBDE formulations, in which PBDE-47 is a main constituent. The European penta-PBDE technical mixture Bromkal 70-5DE was not used as extensively and has been banned for a longer period of time compared to the North American penta-PBDE mixture DE-71 (Birnbaum and Staskal 2004). Exposure to DE-71 is still occurring in North America; therefore, people are being exposed to PBDE-47 on a day-to-day basis. In Europe, exposure to the penta-PBDE formulation has declined and is probably rare nowadays. The PBDE congener pattern in plasma of people exposed several years ago to a penta-PBDE mixture but with little current exposure to this mixture is expected to shift in favor of the more persistent congeners. The estimated half-life ([t.sub.1/2]) of PBDE-153 ([t.sub.1/2] = 6.5 years), a minor component of the penta-PBDE and octa-PBDE mixtures (La Guardia et al. 2006), is three times longer than that of PBDE-47 ([t.sub.1/2] = 1.8 years); therefore, over time PBDE-153 should become the dominant one (Geyer et al. 2004; Hagmar et al. 2000; Thuresson et al. 2006). We (as most other authors) did not measure PBDE-209 in the plasma samples of participants. A decaPBDE mixture, mainly composed of PBDE-209, has replaced the penta-PBDE mixture in several applications in Europe. PBDE-209 has been reported to be the major congener in human serum in one study (Inoue et al. 2006). Although it is unlikely that PBDE-209 would be a dominant congener in North American samples, it might be an important one in European samples, along with lower brominated congeners resulting from its biotransformation.

Considering that PCB levels are age and sex dependent, care should be exerted when comparing PCB-153 levels with those in other studies. Nevertheless, it seems clear from data in Table 5 that PCB-153 levels are lower in North America than in Europe. In a recent Canadian study, Tsuji et al. (2006) reported GM PCB-153 concentrations to be 50.2, 53.6, and 27.0 ng/g lipids in women from Fort Albany (Ontario), Kashechewan (Ontario), and Hamilton (Ontario), respectively. The first two groups were composed of First Nation women. Plasma concentrations measured in Quebec City women are slightly lower than those measured in native women from Ontario but higher than those determined in non-native women from the same province.

Correlation analyses revealed that PBDE-153 was only moderately correlated to PBDE-47 (Figure 1D). We also observed that the contribution of PBDE-47 to [SIGMA]PBDEs increased with increasing concentrations of [SIGMA]PBDEs, whereas the reverse was true for the contribution of PBDE-153 to [SIGMA]PBDEs (Figure 2). These results again suggest that the sources of exposure to PBDE-153 might be different from those of the other PBDEs. Individuals with high PBDE plasma concentrations and a pattern of congeners dominated by PBDE-47 may have been directly exposed to the DE-71 mixture in which PBDE-47 and PBDE-99 are the dominating compounds. Inhalation and dermal contact with technical mixtures of PBDEs in commercial products may contribute substantially to exposure (Sjodin et al. 2004), and several studies in North America have reported dust and indoor exposure to be significant sources of PBDE exposure (Schecter et al. 2005a; Stapleton et al. 2005; Wu et al. 2007). Interestingly, some studies have reported higher plasma levels of PBDEs in children than in adults (Fischer et al. 2006; Thomsen et al. 2002), which may reflect the elevated dust exposure of toddlers (Jones-Otazo et al. 2005).

In individuals with lower PBDE plasma levels, the following lines of evidence indicate that exposure may originate in part from food consumption. We observed that the proportion of total PBDEs represented by PBDE-153 increases as total PBDE concentrations decrease. Similar to PCBs, weathering of PBDEs in the environment should lead to mixtures that are enriched in longlived congeners such as PBDE-153 and lower in less persistent, lower-brominated congeners. The weak but statistically significant correlation observed between PCB-153 and PBDE-153 levels supports the interpretation of a common source of exposure to these compounds. Because exposure to PCBs is mainly through food consumption, this supports our contention that PBDE-153 exposure also occurs in part through food consumption. We did not conduct a complete dietary assessment of participants, but our questionnaire included questions on the consumption of a limited number of food items, including meat. We did not find any relation between meat consumption and plasma concentrations of PBDEs or PCBs. Hence, our results differ from those of Wu et al. (2007), who recently reported a positive association between meat consumption and PBDE concentrations in breast milk samples from 46 first-time mothers living in the greater Boston (Massachusetts) area. The consumption of fish has been linked to higher plasma PCB levels in Great Lakes fish consumers (Humphrey et al. 2000) and in postmenopausal U.S. women (Moysich et al. 2002; Wolff et al. 2005). It would have been interesting to examine relations of plasma PCBs and PBDEs to fish consumption in our study; unfortunately, we did not document fish consumption in our group of Quebec women.

To our knowledge, no study conducted to date has found significant relations between PBDE concentrations in biological samples and age, BMI, parity, breast-feeding duration, or lifestyle habits. In contrast, we identified age and BMI as significant predictors of plasma PCB levels in our sample of Quebec women. Similar associations had previously been reported in the two U.S. studies mentioned above (Moysich et al. 2002; Wolff et al. 2005). The lack of association noted between PBDE levels and age or BMI again supports the idea that the sources of exposure are different for PCBs and PBDEs. The lack of age factor might be explained by the relatively recent introduction of PBDEs, different exposure pathways, and the greater metabolism and elimination of PBDEs compared with PCBs (Johnson-Restrepo et al. 2005).

The final multiple linear regression model for plasma PCB-153 concentrations included age, current BMI, and BMI gain since 18 years of age as predictors and explained 34% of the variance (Table 4). Including BMI gain in the model increased the R2 value by 13% compared with the model containing only age and current BMI as independent variables (data not shown). Including BMI gain in the model also changed the direction of the association between current BMI and PCB-153 levels from negative to positive. Wolff et al. (2005) obtained a similar multivariate model that explained 30% of the variance in plasma PCB concentrations of 999 postmenopausal women on Long Island, New York. The major influence of BMI gain in our model could be explained by corresponding changes in the volume of the adipose tissue compartment, which is the major site of storage for PCBs and other lipophilic compounds. The greater the increase in the volume of the adipose tissue compartment, the greater the dilution of PCB residues and the lower their plasma concentration.

PBB-153 was detected in only 30% of the samples and was neither correlated to PBDEs nor to PCB-153. Levels of PBB-153 were also considerably lower than those of the PBDEs, as previously reported for the U.S. population (Sjodin et al. 2004).

One limitation of our study is the use of a convenience sample of postmenopausal women instead of a random population sample. It is likely that women recruited in breast cancer screening clinics are not representative of the general population of women on several characteristics. Compared with women from the general population, women in our study were more educated and smoked less than women from the general population. This would not however compromise the validity of our results, although they might be less amenable to generalization. Our study provides a first estimate of PBDE body burden in Canadian postmenopausal women. The major strengths of our study are its relatively large sample size and the extensive quality control-quality assurance procedures implemented for the analytical work.

In summary, the concentrations of organobromine compounds in plasma samples of Canadian women were slightly lower than those in the United States. However, the fact that the GM concentration of PBDE-47 is only 6 times lower than that of PCB-153 but the arithmetic means are comparable, clearly indicates the need to monitor PBDEs in human populations on a regular basis. The reason for the extreme levels determined in some women needs to be elucidated; there is also a need to identify the most important sources of human exposure to PBDEs in the general population.

References

Akins JR, Waldrep K, Bernert JT Jr. 1989. The estimation of total serum lipids by a completely enzymatic 'summation' method. Clin Chim Acta 184:219-226.

Birnbaum LS, Hubal EAC. 2006. Polybrominated diphenyl ethers: a case study for using biomonitoring data to address risk assessment questions. Environ Health Perspect 114:1770-1775.

Birnbaum LS, Staskal DF. 2004. Brominated flame retardants: cause for concern? Environ Health Perspect 112:9-17.

Fangstrom B, Hovander L, Bignert A, Athanassiadis I, Linderholm L, Grandjean P, et al. 2005. Concentrations of polybrominated diphenyl ethers, polychlonnated biphenyls, and polychlorobiphenylols in serum from pregnant Faroese women and their children 7 years later. Environ Sci Technol 39:9457-9463.

Fischer D, Hooper K, Athanasiadou M, Athanassiadis I, Bergman [ANGSTROM]. 2006. Children show highest levels of polybrominated diphenyl ethers in a California family of four: a case study. Environ Health Perspect 114:1581-1584.

Geyer H, Schramm KW, Darnerud PO, Aune M, Feicht EA, Fried KW, et al. 2004. Terminal elimination half-lives of the brominated flame retardants TBBPA, HBCD, and lower brominated PBDEs in humans. Organohalogen Compounds 66:3820-3825.

Hagmar L, Sjodin A, Hoglund P, Thuresson K, Rylander L, Bergman [ANGSTROM]. 2000. Biological half-lives of polybrominated diphenyl ethers and tetrabromobisphenol A in exposed workers. Organohalogen Compounds 47:198-201.

Humphrey HE, Gardiner JC, Pandya JR, Sweeney AM, Gasior DM, McCaffrey RJ, et al. 2000. PCB congener profile in the serum of humans consuming Great Lakes fish. Environ Health Perspect 108:167-172.

Inoue K, Harada K, Takenaka K, Uehara S, Kono M, Shimizu T, et al. 2006. Levels and concentration ratios of polychlorinated biphenyls and polybrominated diphenyl ethers in serum and breast milk in Japanese mothers. Environ Health Perspect 114:1179-1185.

Johnson-Restrepo B, Kannan K, Rapaport DP, Rodan BD. 2005. Polybrominated diphenyl ethers and polychlorinated biphenyls in human adipose tissue from New York. Environ Sci Technol 39:5177-5182.

Jones-Otazo HA, Clarke JP, Diamond ML, Archbold JA, Ferguson G, Harner T, et al. 2005. Is house dust the missing exposure pathway for PBDEs? An analysis of the urban fate and human exposure to PBDEs. Environ Sci Technol 39:5121-5130.

La Guardia MJ, Hale RC, Harvey E. 2006. Detailed polybrominated diphenyl ether (PBDE) congener composition of the widely used penta-, octa-, and deca-PBDE technical flameretardant mixtures. Environ Sci Technol 40:6247-6254.

Lind Y, Darnerud PO, Atuma S, Aune M, Becker W, Bjerselius R, et al. 2003. Polybrominated diphenyl ethers in breast milk from Uppsala County, Sweden. Environ Res 93:186-194.

Meerts IA, Letcher RJ, Hoving S, Marsh G, Bergman [ANGSTROM], Lemmen JG, et al. 2001. In vitroestrogenicity of polybrominated diphenyl ethers, hydroxylated PDBEs, and polybrominated bisphenol A compounds. Environ Health Perspect 109:399-407.

Meironyte D, Noren K, Bergman [ANGSTROM]. 1999. Analysis of polybrominated diphenyl ethers in Swedish human milk. A time-related trend study, 1972-1997. J Toxicol Environ Health 58:329-341.

Morland KB, Landrigan PJ, Sjodin A, Gobeille AK, Jones RS, McGahee EE, et al. 2005. Body burdens of polybrominated diphenyl ethers among urban anglers. Environ Health Perspect 113:1689-1692.

Moysich KB, Ambrosone CB, Mendola P, Kostyniak PJ, Greizerstein HB, Vena JE, et al. 2002. Exposures associated with serum organochlorine levels among postmenopausal women from western New York State. Am J Ind Med 41:102-110.

Naert C, Piette M, Bruneel N, Van Peteghem C. 2006. Occurrence of polychlorinated biphenyls and polybrominated diphenyl ethers in Belgian human adipose tissue samples. Arch Environ Contam Toxicol. 50:290-296.

Noren K, Meironyte D. 2000. Certain organochlorine and organobromine contaminants in Swedish human milk in perspective of past 20-30 years. Chemosphere 40:1111-1123.

Sandau CD, Sjodin A, Davis MD, Barr JR, Maggio VL, Waterman AL, et al. 2003. Comprehensive solid-phase extraction method for persistent organic pollutants. Validation and application to the analysis of persistent chlorinated pesticides. Anal Chem 75:71-77.

Schecter A, Papke O, Joseph JE, Tung KC. 2005a. Polybrominated diphenyl ethers (PBDEs) in US computers and domestic carpet vacuuming: possible sources of human exposure. J Toxicol Environ Health A 68:501-513.

Schecter A, Papke O, Tung KC, Joseph J, Harris TR, Dahlgren J. 2005b. Polybrominated diphenyl ether flame retardants in the U.S. population: current levels, temporal trends, and comparison with dioxins, dibenzofurans, and polychlorinated biphenyls. J Occup Environ Med 47:199-211.

Schecter A, Vuk MP, Papke O, Ryan JJ, Birnbaum L, Rosen R. 2003. Polybrominated diphenyl ethers (PBDEs) in U.S. mothers' milk. Environ Health Perspect 111:1723-1729.

Sjodin A, Jones RS, Focant JF, Lapeza C, Wang RY, McGahee EE, et al. 2004. Retrospective time-trend study of polybrominated diphenyl ether and polybrominated and polychlorinated biphenyl levels in human serum from the United States. Environ Health Perspect 112:654-658.

Stapleton HM, Dodder NG, Offenberg JH, Schantz MM, Wise SA. 2005. Polybrominated diphenyl ethers in house dust and clothes dryer lint. Environ Sci Technol 39:925-931.

Thomas GO, Wilkinson M, Hodson S, Jones KC. 2006. Organohalogen chemicals in human blood from the United Kingdom. Environ Pollut 141:30-41.

Thomsen C, Lundanes E, Becher G. 2002. Brominated flame retardants in archived serum samples from Norway: a study on temporal trends and the role of age. Environ Sci Technol 36:1414-1418.

Thuresson K, Hoglund P, Hagmar L, Sjodin A, Bergman [ANGSTROM], Jakobsson K. 2006. Apparent half-lives of hepta-to decabrominated diphenyl ethers in human serum as determined in occupationally exposed workers. Environ Health Perspect 114:176-181.

Tsuji LJS, Wainman BC, Martin ID, Weber JP, Sutherland C, Nieboer E. 2006. Abandoned mid-Canada radar line sites in the western James region of northern Ontario, Canada: a source of organochlorines for First Nations people? Sci Total Environ 370:452-466.

Weiss J, Wallin E, Axmon A, Jonsson BA, Akesson H, Janak K, et al. 2006. Hydroxy-PCBs, PBDEs, and HBCDDs in serum from an elderly population of Swedish fishermen's wives and associations with bone density. Environ Sci Technol 40:6282-6289.

Wolff MS, Britton JA, Teitelbaum SL, Eng S, Deych E, Ireland K, et al. 2005. Improving organochlorine biomarker models for cancer research. Cancer Epidemiol Biomarkers Prev 14:2224-2236.

Wu N, Herrmann T, Paepke O, Tickner J, Hale R, Harvey LE, et al. 2007. Human exposure to PBDEs: associations of PBDE body burdens with food consumption and house dust concentrations. Environ Sci Technol 41:1584-1589.

Torkjel M. Sandanger, (1), (2) Marc Sinotte,(3) Pierre Dumas, (4) Mario Marchand, (4) Courtney D. Sandau, (5) Daria Pereg, (1) Sylvie Berube, (3) Jacques Brisson, (3) and Pierre Ayotte (1), (4)

(1) Unite de recherche en sante publique, Centre hospitalier universitaire de Quebec and Universite Laval, Quebec, Quebec, Canada;

(2) Norwegian Institute for Air Research, Polar Environmental Centre, Troms[empty set], Norway; (3) Unite de recherche en sante des populations, Centre Hospitalier Affilie Universitaire de Quebec, Quebec, Quebec, Canada; (4) Centre de Toxicologie, Institut national de sante publique du Quebec, Quebec, Quebec, Canada; (5) Trium Environmental Solutions Inc., Cochrane, Alberta, Canada

Address correspondence to P. Ayotte, Unite de recherche en sante publique CHUQ-CHUL and INSPQ, 945 avenue Wolfe, [4.sup.e] etage, Quebec, QC, Canada G1V 5B3. Telephone: [phone], ext. 4654. Fax: [phone]. E-mail: [e-mail]

This study was supported by the Canadian Breast Cancer Research Alliance (Etiology and Prevention Grant 013568). M.S. was supported by studentships from the Canadian Institutes of Health Research and the National Cancer Institute of Canada.

C.D.S. is employed by Trium Environmental Solutions Inc., an environmental consulting firm. The authors declare they have no competing financial interests.

Received 26 March 2007; accepted 23 July 2007.